Emory University's Suresh S. Ramalingam Honored as Young Investigator of the Year
 

Suresh S. RamalingamThis year's Young Investigator Award, the ECOG Research and Education Foundation's most prestigious honor, was presented to Suresh S. Ramalingam, MD, at the ECOG-ACRIN Spring 2013 Group Meeting earlier this month in Atlanta. The award recognizes a young physician who has made substantial scientific and administrative contributions to the organization and to the field.

 

Read more...

  

Guide to ASCO 2013

   

In an effort to provide you with a central source of information about our ECOG-ACRIN presence at the upcoming ASCO meeting, we have added a searchable listing to the ECOG-ACRIN website. Please follow the link below for access to the combined table of all presentations, posters, and publications pertaining to ECOG, ACRIN, and PrECOG studies. The table includes titles, lead authors, lead committees, dates/times, locations, and links to the abstracts. Users may save or print the complete listing by selecting the PDF Download option below the table.

 

Guide to ECOG-ACRIN Presentations at ASCO 2013

  
New Vice Chair Named

 

Joseph A. Sparano Joseph A. Sparano, MD, was named Vice Chair of the ECOG-ACRIN Cancer Research Group at the Spring 2013 Group Meeting in Atlanta. Dr. Sparano, from member institution Albert Einstein College of Medicine/Montefiore Medical Center, is a medical oncologist and clinical researcher who joined ECOG in 1991 and has held the position of Co-Chair or Chair of the ECOG Breast Committee since 2002.
 

The Vice Chair position was established in the ECOG-ACRIN constitution to provide assistance to the Group Co-Chairs in defining research priorities and implementing the Group's broad research portfolio, which includes programs in Cancer Control and Outcomes, Therapeutic Studies, and Biomarker Sciences. 

 

A similar position existed in ECOG and was held by Peter J. O'Dwyer, MD, at the time of the merger. Dr. O'Dwyer is a practicing medical oncologist and clinical researcher at the University of Pennsylvania in Philadelphia and Co-Chair of the newly formed Scientific Planning Committee of ECOG-ACRIN. At the General Session of the recent Group meeting, Group Co-Chairs Robert L. Comis, MD, and Mitchell D. Schnall, MD, PhD, thanked Dr. O'Dwyer for his many years of service as Vice Chair of ECOG and acknowledged his guidance during the merger of ECOG and ACRIN.

 

Dr. O'Dwyer will continue his leadership as Chair of the Board of Managers for PrECOG, LLC.

 

Learn more about Dr. Sparano by reading the press release.

  
New England Journal of Medicine Publishes First-Screen Examination Analysis from NLST

Physicians have more information to share with their patients about the use of low-dose computed tomography (low-dose CT) inlung cancer screening based on data from the first of three planned analyses of annual screening examinations performed in National Lung Screening Trial (NLST) participants. The findings were published in the New England Journal of Medicine on May 23, 2013.  

 

Read more...

  
E1512 Trial Spotlight  

 

We recently conducted a Q&A with Joel Neal, MD, PhD, study chair for E1512, a new trial that activated on February 7, 2013. The development of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors is a vexing clinical problem. In E1512, a randomized, three-arm phase II trial, the ECOG-ACRIN Thoracic Committee seeks to improve the efficacy of erlotinib and elucidate the role of cabozantinib as second- or third-line therapy in patients with EGFR wild-type non-small cell lung cancer. The article provides relevant information for sites interested in providing this trial for their patients. 

 

Read more...

  
 
The Paul Carbone, MD Fellowship Award was presented to Patrick Forde, MD, a medical oncology fellow at Johns Hopkins University, at the ECOG-ACRIN Spring 2013 Group Meeting earlier this month in Atlanta. The purpose of the award, which is given by the ECOG Research and Education Foundation, is to develop and promote excellence in clinical trials, leading to improvements in cancer care. 
  

Biospecimens from E5194 Trial Aid Researchers in Validation of Oncotype DX DCIS Score


On May 2, 2013, the Journal of the National Cancer Institute published positive results from a prospective study establishing that the Oncotype DX DCIS Score goes beyond traditional clinical and pathologic measures to predict the 10-year risk of local recurrence in women with ductal carcinoma in situ (DCIS) who are treated by local excision. This finding will help to guide radiation treatment decision-making, as traditional clinical and pathologic criteria are insufficient to define a low-risk population for whom excision alone may be adequate.

  

Congratulations are in order for lead author Lawrence J. Solin, MD, FACR, FASTRO, and colleagues from the Breast Committee and Genomic Health, Inc. 

  

  
Trial Activations 
 
The following trial were activated between January 1 and
May 15, 2013:

Thoracic - ACRIN 4703 aka DECAMP-1

Detection of Early Lung Cancer Among Military Personnel Study 1 (DECAMP-1): Diagnosis and Surveillance of Indeterminate Pulmonary Nodules  

Chairs: Avrum Spira, MD, MSc (Boston University), and Mitchell D. Schnall, MD, PhD (University of Pennsylvania)

Accrual Goal: 500

Date Activated: January 2013

Projected Completion: December 2016

 

Thoracic - E1512 

A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib plus Cabozantinib as 2nd or 3rd Line Therapy in Patients with EGFR Wild-Type NSCLC

Chair: Joel Neal, MD, PhD (Stanford University)

Co-Chair: Heather Wakelee, MD (Stanford University)

Accrual Goal: 117

Date Activated: February 7, 2013

Projected Completion:  April 2014

 

Gastrointestinal - E2211

A Randomized Study of Temozolomide or Temozolomide + Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors 

Chair: Pamela L. Kunz, MD (Stanford University)

Co-Chair: Halla S. Nimeiri, MD (Northwestern University)

Imaging Co-Chairs: Terence Z. Wong, MD, PhD (Duke University), and Daniel L. Rubin, MD, MS (Stanford University)

Accrual Goal: 145

Date Activated: April 11, 2013

Projected Completion: December 2014


Lymphoma - PrE0401

Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients with Previously Untreated Low Tumor Burden Indolent Non-Hodgkin Lymphoma 

Substudy: Evaluation of Corrected QT (QTc) Interval and Pharmacokinetic Parameters in Patients Participating in GA101 (Obinutuzumab) 

Study Chair: Stephen M. Ansell, MD, PhD (Mayo Clinic)

Co-Chair: Brad Kahl, MD (University of Wisconsin)

Accrual Goal: 150

Date Activated: May 6, 2013

Projected Completion: February 2017

 

Cancer Control - E1Z11

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) 

Chair: Vered Stearns, MD (Johns Hopkins University)

Co-Chair: Victor T. Chang, MD (VA New Jersey Health Care System) 

Accrual Goal: 1000

Date Activated: May 8, 2013

Projected Completion: September 2015

  
Trial Closures
 

The following trials were reported for closure between January 1 and May 15, 2013:

 

Lymphoma - E1F05 

Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma 

Date Closed: April 12, 2013

  

Leukemia - E2903

Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab (PCR) Followed By Campath-1H For Previously Treated Relapsed or Refractory Patients With Chronic Lymphocytic Leukemia 

Date Closed: May 6, 2013

  
Trial Approvals

The following trials were approved between January 1 and May 15, 2013:

 

Head and Neck - E1311                     

A Randomized, Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence 

Pre-activation: June 15, 2013

Activation: July 21, 2013

 

Thoracic - E2512                     

A Phase I/Randomized Phase II Study of Docetaxel with or without AZD4547 in Recurrent FGFR1-Amplified Squamous Non-Small Cell Lung Cancer 

Activation: June 26, 2013

 

Myeloma - E1A11

Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma 

Activation: Date to come

May 2013
In This Issue
Young Investigator Award
Guide to ASCO 2013
New Vice Chair Named
New NLST Analysis in NEJM
E1512 Trial Spotlight
2013 Carbone Award
DCIS Score Validation in JNCI
Trial Activations
Trial Closures
Trial Approvals
Group Meeting Survey
New Trial Education Pages
How was your Group meeting experience?
 

As we strive to accommodate the increase in the number of committees and working groups as a result of the merger, the format of the semiannual Group meeting continues to change. To gauge your level of satisfaction with the recent meeting, we've prepared a brief survey to gather your feedback. The survey should take less than 4 minutes to complete. Please take a moment to...

 

Take this survey

 

Your feedback is greatly appreciated and will help in the planning of future meetings. Thank you for your time!

Now Posted:
New Educational Materials at ECOG-ACRIN.org
 
Select the trial number below to go directly to the material:


    
    Visit the site:
 
logo link to site 
 
 
 
 
 
Have a suggestion for a future newsletter topic?
  

ECOG-ACRIN Cancer Research Group  |  Office of Communications
 1818 Market Street, Suite 1100, Philadelphia, PA 19103 | (215) 789-3631